Cholesterol and HDL-cholesterol values in women during use of subdermal implants releasing levonorgestrel.
Plasma concentrations of cholesterol, HDL-cholesterol, and levonorgestrel were determined in two groups of women using levonorgestrel-releasing subdermal implants. One group used six capsules (NORPLANT)*; the other six covered rods. Plasma concentrations of levonorgestrel among NORPLANT users averaged 700 pg/ml in the first two weeks of use, decreased to 300 pg/ml at 8 weeks, and to about 230 pg/ml by 50 weeks. Concentrations among covered rod users were 1.4 to 1.7 times higher at comparable time periods. Total serum cholesterol and HDL-cholesterol were decreased as compared with controls at all sampling intervals during the 114 weeks of the trial, although the differences did not meet tests of significance at all time periods. Decreases during the test period were of the order of 10 percent, except for total cholesterol among covered rod users where the decrease was less. Cholesterol to HDL-cholesterol ratios did not differ significantly from control values at any sampling period.
D000328:Adult; D002214:Capsules; D002784:Cholesterol / Q000097:blood*; D008076:Cholesterol, HDL / Q000097:blood*; D004343:Drug Implants; D005260:Female; D006801:Humans; D016912:Levonorgestrel; D009644:Norgestrel / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood; D013237:Stereoisomerism
D002214:Capsules; D008076:Cholesterol, HDL; D004343:Drug Implants; D009644:Norgestrel; D016912:Levonorgestrel; D002784:Cholesterol